BiotechTube

CS7017 + irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Colorectal Cancer

Conditions

Colorectal Cancer, Neoplasms, Colorectal

Trial Timeline

Sep 1, 2009 → Apr 1, 2013

NCT ID
NCT00967616

About CS7017 + irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)

CS7017 + irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI) is a phase 2 stage product being developed by Daiichi Sankyo for Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00967616. Target conditions include Colorectal Cancer, Neoplasms, Colorectal.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00967616Phase 2Completed

Competing Products

20 competing products in Colorectal Cancer

See all competitors
ProductCompanyStageHype Score
Cetuximab + Oxaliplatin + CapecitabineEli LillyPhase 2
52
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FUEli LillyPhase 2
52
ZN-c3 + Encorafenib + CetuximabZentalis PharmaceuticalsPhase 1
25
ALIMTA + OxaliplatinEli LillyPhase 2
52
eFT508 + AvelumabeFFECTOR TherapeuticsPhase 2
44
Bevacizumab + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 1/2
41
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 2
52
FOLFIRI + FOLFOX-4 + FOLFIRI-HD + FOLFOX-7 + FOLFIRINOXChugai PharmaceuticalPhase 2/3
65
Gemcitabine and UFTE chemotherapyYuhanPhase 2
52
CPT-11 and TS-1 + CPT-11, 5-FU and l-LVDaiichi SankyoPhase 2/3
65
CPT-11 based regimensDaiichi SankyoPre-clinical
23
Tivantinib + Placebo + Cetuximab + IrinotecanDaiichi SankyoPhase 1/2
41
DS-8201a 5.4 mg/kg Q3W + DS-8201a 6.4 mg/kg Q3WDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
CS-1008 + irinotecanDaiichi SankyoPhase 2
52
CS-7017 + PlaceboDaiichi SankyoPhase 2
52
Patritumab DeruxtecanDaiichi SankyoPhase 2
52
CS-1008 + FOLFIRIDaiichi SankyoPhase 1
33
DS-8273a + nivolumabDaiichi SankyoPhase 1
33
DS-8201aDaiichi SankyoPhase 2
52

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85